These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38772291)

  • 1. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.
    Yu L; Wang YD; Yan ZW; Zhang LY; Li S
    Bioorg Chem; 2024 Jul; 148():107480. PubMed ID: 38772291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
    Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
    Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
    Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
    Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
    Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
    Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors.
    Wu J; Wang X; Yao Y; Du N; Duan L; Gong P
    Bioorg Chem; 2024 Oct; 151():107556. PubMed ID: 39068717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
    Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamoylation at C-8 position of natural 3-arylcoumarin scaffold for the discovery of novel PARP-1 inhibitors with potent anticancer activity.
    Lu G; Zou Z; Xin M; Meng Y; Cheng Z; Du Z; Gu J; Zhang X; Zou Y
    Eur J Med Chem; 2024 Nov; 277():116726. PubMed ID: 39116535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
    Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
    Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
    Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
    J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
    Zhou Y; Tang S; Chen T; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
    J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
    Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
    Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
    Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
    Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs.
    Li S; Li XY; Zhang TJ; Kamara MO; Liang JW; Zhu J; Meng FH
    Bioorg Chem; 2020 Jan; 94():103385. PubMed ID: 31669094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.